Draft Guidance on Alectinib Hydrochloride

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

Active Ingredient: Alectinib hydrochloride
Dosage Form; Route: Capsule; oral
Recommended Studies: Two studies

1. Type of study: Fasting
   Design: Single-dose, two-way crossover in vivo
   Strength: Eq 150 mg base at a dose of 600 mg (150 mg x 4)
   Subjects: Healthy males and non-pregnant, non-lactating females, general population
   Additional comments: a. Female subjects should not be pregnant or lactating, and should practice abstention or contraception during the study and for one week after the final dose since ALECENSA can cause fetal harm when administered to a pregnant woman. Based on genotoxicity findings, males with female partners of reproductive potential should use effective contraception during treatment with ALECENSA and for three months following the final dose. b. Ensure adequate washout periods between treatments in the crossover studies due to its long terminal elimination half-life. Also consider using a parallel study design due to its long half-life. For long half-life drug products with low intra-subject variability in distribution and clearance, an AUC truncated to 72 hours may be used in place of AUC_{0-t} or AUC_{0-\infty}. For either a crossover or parallel study, sample collection time should be adequate to ensure completion of gastrointestinal transit of the drug product and absorption of the drug substance. Collect sufficient blood samples in the bioequivalence studies to adequately characterize the peak concentration (C_{max}) and time to reach peak concentration (t_{max}).

2. Type of study: Fed
   Design: Single-dose, two-way crossover in vivo
   Strength: Eq 150 mg base at a dose of 600 mg (150 mg x 4)
   Subjects: Healthy males and non-pregnant, non-lactating females, general population
   Additional comments: See comments above.

Analytes to measure (in appropriate biological fluid): Alectinib in plasma
Bioequivalence based on (90% CI): Alectinib
Waiver request of in vivo testing: Not applicable.

Recommended Oct 2016
**Dissolution test method and sampling times:** The dissolution information for this drug product can be found on the FDA-Recommended Dissolution Methods website available to the public at the following location: [http://www.accessdata.fda.gov/scripts/cder/dissolution/](http://www.accessdata.fda.gov/scripts/cder/dissolution/). Conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the abbreviated new drug application (ANDA).